substitute for tirzepatide Mounjaro (tirzepatide) is a dual incretin agonist targeting both GLP-1 and GIP receptors. It improves glycaemic control by enhancing insulin secretion, suppressing glucagon, and delaying gastric emptying — which also leads to Oral Tirzepatide Pill: FDA Status

Comments Why are GLP-1RAs a 1B, and follow metformin and SGLT2i

Realistic expectations regarding timeline and magnitude of improvement are essential

Although publication bias should always be considered (Jennings & Van Horn, 2012), neuroimaging studies are likely more susceptible to confirmation bias due to high analytical flexibility (Mller et al., 2018)

As informaes so do G1

Some patients and clinicians prematurely conclude the medication is ineffective before reaching therapeutic doses of 10-15 mg weekly

But as political divides widen, future enforcement may come more from aligned coalitions of AGs than broad federal action